Teva’s Digital Inhaler is Approved by FDA
January 4, 2019
It’s quite tough for doctors to monitor patients’ proper medication once they leave the chamber (or hospital). Teva Pharmaceuticals, a Jerusalem based company, has recently been permitted for launching a medically prescribed digital inhaler linked to a mobile app by US FDA. Initially they will bring this sensor-packed digital device in a small volume with partnered health care system. Then, it is planned to launch nationally by 2020, said the officials of the company.
Previously, Gecko health Innovations, Cambridge, Massachusetts-based company, produced smart inhalers, CareTRx, to fight against chronic respiratory diseases like asthma and COPD. The company had been undertaken by Teva Pharmaceuticals and afterwards manufactured this product. ProAir Digihaler of Teva Pharmaceuticals is capable of curing bronchospasm of patients aging four years or elder with reversible obstructive pulmonary diseases like asthma, COPD, exercise- induced bronchospasm (EIB). The digital albuterol dispenser contains a built-in module for the detection and measurements of each use and the recorded data is assembled in a Bluetooth-connected mobile app. The data is sharable with the doctors and patients can check their usage whenever they want. Previously, the physicians can’t monitor whether a patient is taking inhaler properly or not. The FDA approval of ProAir Digihaler will promote the doctors-patients interaction and manage asthma more effectively.
This innovation is quite significant in the field of medication and also a step forward to the evolution of medical technology.
Image: representation of mobile and app purpose only
